Implants that control medication delivery for treating chronic eye diseases
Co-Delivery Dose-Controllable Implants for Advanced Chronic Eye Disease Treatment
This study is testing new implants that can slowly release medicine to help treat chronic eye diseases, making it easier for patients by reducing the need for frequent eye injections.
Quick facts
| Grant type | R03 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Cincinnati NIH-funded |
| Lab location | 1 site (Cincinnati, United States) |
| Project ID | NIH-10864041 on NIH RePORTER |
What this research studies
This research focuses on developing innovative implants that can deliver medication in a controlled manner to treat chronic eye diseases like diabetic macular edema and wet age-related macular degeneration. By using these implants, the goal is to reduce the need for frequent and invasive eye injections, which can lead to complications and discomfort for patients. The approach involves combining anti-inflammatory and anti-VEGF therapies to improve treatment efficacy while minimizing side effects. Patients will be monitored to assess the effectiveness and safety of these implants over time.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals suffering from chronic posterior eye diseases such as diabetic macular edema, wet age-related macular degeneration, or non-infectious posterior uveitis.
Not a fit: Patients with acute eye conditions or those who do not have chronic eye diseases may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could significantly improve the quality of life for patients with chronic eye diseases by reducing the frequency of injections and associated complications.
How similar studies have performed: Previous research has shown promise in using combination therapies for chronic eye diseases, indicating that this approach may lead to meaningful advancements in treatment.
Where this research is happening
Cincinnati, United States
- University of Cincinnati — Cincinnati, United States (Active)
Researchers
- Principal investigator: Park, Yoonjee — University of Cincinnati
- Study coordinator: Park, Yoonjee
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.